Sanofi settles EU antitrust probe over disparaging a rival flu vaccine, no fine
- EU antitrust regulators accepted concessions from Sanofi to close a probe into an allegedly misleading campaign that disparaged a rival flu vaccine.
- Because the case ended on accepted commitments, Sanofi avoids a fine.
- Details of the commitments are behind STAT's paywall; this summary rests on the public excerpt only.
💡 Points
A commitments decision is the cheap exit: no infringement finding, no fine, and little disruption to the flu franchise's commercial playbook. The wider signal is that regulators are watching comparative vaccine messaging, so rivals' medical-affairs and marketing teams will likely be more careful about how they position products against competitors.